Abbvie submits all-oral hep C application to U.S. regulators; Kala's eye delivery platform spurs $22.5M funding round;

> Abbvie ($ABBV) submitted an FDA application for its all-oral hepatitis C treatment. Story

> Kala Pharmaceuticals, co-founded by Robert Langer, closed a $22.5 million funding round, looking to push forward its ocular treatments that use the company's mucus-penetrating particle delivery platform. Article

> Nitto Denko completed dose escalation of its Phase Ia RNAi-based treatment for fibrosis in the liver and other organs. The siRNA is delivered with a lipid nanoparticle delivery system the company developed in collaboration with Yoshiro Niitsu of Sapporo Medical University. Release

> Ocular Therapeutix will present Phase II data regarding its ReSure Sealant hydrogel with sustained-release dexamethasone at the upcoming American Society of Cataract and Refractive Surgery annual symposium in Boston. Release

> Researchers at the University of Kentucky have developed a method to create heat-resistant nanostructures--including drug delivery structures--using RNA as a building tool. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.